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Abstract 9 
Residing at the interface of chemistry and biotechnology, artificial metalloenzymes 10 
offer an attractive technology to combine the versatile reaction repertoire of transition 11 
metal catalysts with the exquisite catalytic features of enzymes. While earlier efforts in 12 
this field predominantly comprised studies in well-defined test-tube environments, a 13 
trend towards exploitation of artificial metalloenzymes in more complex environments 14 
has recently emerged. This includes the integration of these artificial biocatalysts in 15 
enzymatic cascades and reaches out to their utilization in whole cell biotransformations 16 
and in vivo, opening up entirely novel prospects for both preparative chemistry and 17 
synthetic biology. Here we highlight selected recent developments with a particular 18 
focus on challenges and opportunities for the in vivo application of artificial 19 
metalloenzymes. 20 
 21 
<Trends Box> 22 
Artificial metalloenzymes (ArMs) are an emerging form of non-natural biocatalysts, 23 
which allow to create biocatalytic novelty with potential applications in preparative 24 
chemistry and synthetic biology. 25 
Initial engineering efforts for ArM creation have been conducted in well-defined in vitro 26 
systems based on purified protein variants and therefore systematic directed evolution 27 
of ArMs as well as their introduction into cellular pathways has been hitherto largely 28 
limited. 29 
More recently, a trend towards utilization of ArMs in whole-cell systems and in vivo has 30 
emerged, which is associated with a number of critical obstacles yet to be overcome.  31 
This transition shows great promise for the sustainable production of commodity 32 
chemicals and new-to-nature metabolites using ArMs. 33 
<\Trends Box> 34 
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Artificial Metalloenzymes 35 
 36 
Artificial metalloenzymes (ArMs hereafter; see definition in Box 1) are a class of 37 
synthetic biocatalysts, which combine attractive features of enzymatic and transition 38 
metal catalysis. While enzymes are well-known for their exquisite catalytic 39 
performance comprising high reaction rates, turnover numbers (TONs) and selectivity 40 
as well as mild reaction conditions [1, 2], they are limited to the arsenal of reactions 41 
that has emerged during natural evolution [3]. In contrast, transition metal catalysts 42 
offer a broad range of reaction mechanisms, many of which are not found amongst 43 
natural enzymes, providing a valuable toolbox for synthetic chemistry. However, 44 
homogeneous catalysts are often incompatible with natural enzymes and numerous 45 
cellular metabolites. Combining these two seemingly unrelated domains by creating 46 
ArMs, which catalyze new-to-nature reactions and, importantly, are genetically 47 
encoded and hence evolvable, offers great synergistic potential. This was first 48 
demonstrated by Wilson and Whitesides who, by incorporation into avidin, endowed a 49 
biotinylated rhodium catalyst with enantioselectivity for a hydrogenation reaction, while 50 
in the absence of the protein racemic product was formed [4]. The potential of ArMs 51 
has since been demonstrated for several protein scaffolds and target reactions. As this 52 
is the subject of several excellent reviews (e.g. [3, 5-9]) it shall not be comprehensively 53 
discussed here. 54 
Previous work on ArMs predominantly focused on studies of reactions in defined in 55 
vitro systems relying on purified protein variants. Consequently, their genetic 56 
optimization was limited to few target residues. Screening of large numbers of genetic 57 
variants, however, bears great potential for enzyme development, which was recently 58 
demonstrated for a highly efficient artificial aldolase [10]. 59 
In parallel, a trend towards application of ArMs in more complex systems is prevailing, 60 
which includes employing them in cell-free extracts [11, 12], whole-cell 61 
biotransformations [12-16], and in vivo [17, 18], as well as their introduction into multi-62 
enzyme reaction systems including regulation [19-23]. This transition towards 63 
integration of bioorthogonal chemistry into synthetic biological systems might 64 
drastically accelerate directed evolution of ArMs and by far exceeds their 65 
aforementioned potential for preparative chemistry [24, 25]. One can envision the use 66 
of ArMs in novel biochemical pathways to produce previously inaccessible compounds, 67 
which could contribute to the inevitable transition of our petroleum-based economy 68 
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towards sustainable production. While this transition is arguably cumbersome, the field 69 
of ArMs is currently experiencing disruptive change and in vivo application seems well 70 
within reach. This review highlights important recent proceedings in the creation of 71 
novel reactivities using ArMs and emphasizes critical challenges and opportunities for 72 
their utilization in living cells. 73 
 74 
<Box 1> 75 
Definition of Artificial Metalloenzymes (ArMs) 76 
For the purpose of this review, an artificial metalloenzyme (ArM) shall be defined as a 77 
protein (>50 amino acid residues) which contains at least one metal ion playing a 78 
crucial role in catalysis and which can be regarded as “artificial” due to at least one of 79 
the following attributes: 80 
 81 
• it contains a non-canonical catalytic metal (i.e. not found in natural enzymes) 82 
• it catalyzes a non-natural reaction (-mechanism) (incl. repurposing of natural 83 
metalloenzymes!) 84 
• its protein scaffold is designed de novo 85 
 86 
ArMs are composed of two basic components, a protein part or “scaffold”, which in its 87 
apo-form is catalytically inactive, and a metal component or “cofactor”, which includes 88 
a metal ion or a complex thereof. The definition applied in this review excludes metal-89 
containing peptide catalysts, (< 50 amino acid residues) which, while undoubtedly an 90 
important area of research, shall not be reviewed herein but have been discussed 91 
elsewhere [26, 27]. 92 
<\Box 1> 93 
 94 
 95 
 96 
 97 
 98 
 99 
 100 
 101 
 102 
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ArMs for the Creation of Catalytic Novelty 103 
 104 
Engineering of enzymes for new-to-nature reactions bears great potential for industrial 105 
applications providing efficient and ecologically friendly solutions for synthetic 106 
chemistry [7]. Different approaches have been pursued to generate catalytic novelty 107 
using metalloenzymes, which can be roughly divided into i) repurposing of natural 108 
enzymes, ii) enzyme (re-)design, and iii) artificial cofactor approaches (Figure 1). 109 
 110 
 111 
 112 
Figure 1. Strategies for the generation of emerging catalytic activity by creation of artificial 113 
metalloenzymes (ArMs). Natural metalloenzymes can be repurposed to catalyze entirely novel 114 
reactivities provided a promiscuous enzyme candidate can be identified which exhibits at least 115 
rudimentary side reactivity for the desired reaction. In the absence of the latter metalloenzymes with 116 
basic activity can be designed, either from scratch (de novo) or relying on existing proteins into which 117 
active metal centers can be introduced (redesign). Alternatively, artificial cofactors with intrinsic activity 118 
can be introduced to endow the cognate protein with activity. This can be achieved by reconstituting 119 
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natural metalloenzymes with synthetic metal(-cofactors) or by introducing the latter into proteins without 120 
native metal-binding properties (e.g. by covalent or supramolecular anchoring). Once minimal activity is 121 
established by one of the aforementioned methods, directed evolution can be used to evolve the ArMs 122 
for the desired application (for a selection of recent studies applying the different strategies please refer 123 
to Table 1). 124 
 125 
Repurposing relies on inherent promiscuous activity of natural enzymes and directed 126 
evolution of this feature to practically useful extents [9]. In the context of ArMs, this 127 
strategy has been most successfully applied to iron catalysis with heme proteins [5]. 128 
Spearheaded by Arnold and coworkers in 2013, who evolved cytochrome P450 129 
variants to enantio- and diastereoselective enzymes for cyclopropanation of styrene 130 
[13, 16], an array of compelling studies emphasizing the plasticity of these proteins 131 
followed. This comprised development of biocatalysts for cyclopropanation [28] with 132 
complementary stereoselectivity [14] and trifluoromethyl substitution [15], for olefin 133 
aziridination [29], as well as for nitrene insertion to create C-N [30-33] and S-N [34, 35] 134 
bonds and carbene insertion into N-H [36, 37] and S-H [38] bonds, to name but a few. 135 
Probably one of the most progressive recent studies is the repurposing of a cytochrome 136 
c variant from Rhodothermus marinus to form carbon-silicon bonds at high TONs and 137 
enantioselectivities [12].  Beyond the P450 domain other natural metalloenzymes have 138 
been repurposed, such as iron halogenase SyrB2 from Pseudomonas syringae B301D 139 
to catalyze azidation and nitration of non-activated aliphatic C-H bonds [39]. 140 
Unfortunately, for some chemically desirable transformations Nature does not (yet) 141 
provide promiscuous reactivity, which is essential for any directed evolution effort [9]. 142 
In these cases, rational protein design can offer valuable means to introduce entirely 143 
new reactivity into proteins, either by de novo design of synthetic (bottom-up) or based 144 
on existing protein folds (top-down). The group of Pecoraro, for instance, has designed 145 
a synthetic three-stranded coiled coil protein with a catalytically competent Zn(II) and 146 
a stabilizing Hg(II) center [40, 41]. This protein exhibited hydrolytic activity for p-147 
nitrophenyl acetate and CO2 hydration, the latter of which was later highly improved in 148 
another synthetic Zn-binding scaffold [42]. However, successful examples of strict de 149 
novo design of ArMs remain scarce [40], likely due to difficulties in designing stable 150 
folds with catalytic metal-binding sites from scratch. As an alternative, redesign of 151 
natural proteins to endow these with non-inherent catalytic activities was applied [17, 152 
43]. In a seminal study Baker and coworkers applied computational design and 153 
directed evolution to create a highly active organophosphate hydrolase based on a 154 
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mononuclear zinc deaminase, emphasizing the synergistic potential of these two 155 
methods [43]. 156 
A widely adopted and arguably pragmatic approach is the introduction of non-canonical 157 
catalytic metal(-complexes) (i.e. artificial cofactors) into proteins using appropriate 158 
anchoring strategies (vide infra). Synthetic heme derivatives have been used in which 159 
either iron is replaced by metals including Mn, Co and Ir [11, 31, 44-46] or the structure 160 
of the porphyrin ligand is altered [44, 47]. Oohora et al. reconstituted myoglobin from 161 
horse heart with a Mn-porphycene cofactor to afford an ArM for the challenging 162 
hydroxylation of C(sp3)-H bonds [44]. The group of Hartwig recently introduced Ir-163 
containing heme into mutants of apo-myoglobin from Physeter macrocephalus creating 164 
ArMs for intramolecular C(sp3)-H insertion of carbenes and intermolecular carbene 165 
addition to olefins, albeit at low activities [45]. This concept was later improved using a 166 
thermophilic protein variant and directed evolution to afford highly active variants for 167 
carbene insertion into C(sp3)-H [46] and later extended to C-H amination [11]. Likewise, 168 
artificial cofactors without natural equivalent have been used. These are fully synthetic 169 
metal complexes with a suitable anchoring moiety for the specific localization in the 170 
corresponding protein. Lewis and colleagues covalently anchored dirhodium 171 
complexes in the  , -barrel protein tHisF [48] and later in a prolyl oligopeptidase [49], 172 
yielding ArMs for cyclopropanation and Si-H bond insertion reactions. The latter host 173 
protein was evolved by iterative site-directed mutagenesis to a water-tolerant, 174 
enantioselective cyclopropanation enzyme [49]. Following pioneering works of 175 
Whitesides [4] several ArMs have been created relying on biotinylated transition metal 176 
cofactors and (strept-)avidin as the cognate host protein. Important recent reports 177 
exploiting this strategy are the creation of a rhodium ArM for asymmetric C-H activation 178 
by Hyster et al. [50], which exhibited nearly 100-fold rate acceleration compared to the 179 
free rhodium complex, as well as the combination of an iridium-based artificial transfer 180 
hydrogenase with several natural enzymes in one-pot reaction cascades by Köhler et 181 
al. [19]. Albeit in vitro, the latter represents an important step towards ArM application 182 
in complex reaction networks and artificial pathways. In vivo applications in mind, we 183 
have recently reported on the development and directed evolution of artificial 184 
metathases by combining a ruthenium-based cofactor with streptavidin in the 185 
periplasm of E. coli in aqueous medium under aerobic conditions [18]. Relying on the 186 
production of fluorescent umbelliferone by olefin metathesis, this enabled genetic 187 
optimization directly on whole cells without processing or purification of protein 188 
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variants, thereby significantly increasing the throughput. The resulting metathases 189 
exhibited significantly improved activities for the screening substrate, albeit at low 190 
TONs, and for other di-olefin compounds. 191 
Hence, the presented ensemble of recent developments in the ArM field (Table 1), 192 
while not comprehensive and likely subjective, emphasizes their potential for the 193 
creation of catalytic novelty in bio- and transition metal catalysis. 194 
 195 
 196 
Challenges for In Vivo Application of ArMs 197 
 198 
Despite significant recent advances, the in vivo implementation of ArMs imposes 199 
stringent challenges on chemists and metabolic engineers (Figure 2). Important 200 
obstacles include: i) choice of and expression strategy for the scaffold protein, ii) 201 
cellular uptake of metal cofactors, iii) intracellular ArM assembly, and iv) 202 
bioorthogonality of ArM (-reaction) and host cell (i.e. inhibition and cytotoxicity), which 203 
are individually discussed below. 204 
 205 
 206 
 207 
Figure 2. Critical challenges for in vivo implementation of ArMs. A number of obstacles need to be 208 
overcome in order to successfully implement ArMs in living cells. These include: i) the choice of the 209 
respective scaffold protein and appropriate ways for its expression, ii) cellular cofactor uptake and iii) 210 
subsequent assembly of the holoenzyme, as well as iv) considerations regarding the mutual interaction 211 
between the ArM and the host cell (i.e. inhibition and cytotoxicity). M: metal atom/ion, L: Ligand, 212 
GSH/GSSG: reduced/oxidized glutathione (disulfide). 213 
 214 
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Table 1. Key features of selected recent studies on ArM development 215 
Cofactora Proteina Anchoring Reaction Whole Cell Application Refs 
Repurposing 
Fe(III), heme 
Cytochrome 
P450/411BM3 
Non-
covalent 
Cyclopropanation of styrene 
derivatives 
No [13] 
Yes [16] 
Aziridination of aryl olefins Yes [29] 
C-H amination (intramolecular) 
Yes [30] 
No [32] 
C-H amination (intermolecular) Yes [33] 
Sulfimidation 
No [34] 
Yes [35] 
Carbene insertion into N-H Yes [36] 
Rhodothermus 
marinus 
cytochrome c  
Carbene insertion into Si-H Yes [12] 
Sperm whale 
myoglobin 
Cyclopropanation of styrene and 
other aryl olefins 
No 
Yes 
[28] 
[14] 
Cyclopropanation of trifluoromethyl 
substituted styrene and aryl olefins Yes [15] 
Carbene insertion into N-H No [37] 
Carbene insertion into S-H No [38] 
C-H amination (intramolecular) No [31] 
Fe(II), 
haloferryl 
Pseudomonas 
syringe B301D 
halogenase SyrB2 
Direct/ 
dative Azidation and nitration of C-H No [39] 
(Re-)design 
Zn(II) + Hg(II) Synthetic triple coiled coil 
Direct/ 
dative 
Hydrolysis of p-nitrophenyl acetate 
and CO2 hydration No [40] 
Zn(II) 
Synthetic triple 
coiled coil CO2 hydration No [42] 
Mouse adenosine 
deaminase Organophosphate hydrolysis No [43] 
Cytochrome cb562 β-lactam hydrolysis Yes [17] 
Artificial cofactors 
Mn(III), 
porphycene 
Horse heart 
myoglobin 
Non-
covalent 
Hydroxylation of C-H No [44] 
Ir(III)-(Me), 
heme 
Physeter 
macrocephalus 
myoglobin  
Carbene insertion into C-H and 
carbene olefin addition No [45] 
Sulfolobus 
solfataricus P450 
CYP119 
Carbene insertion into C-H No [46] 
C-H amination (intramolecular) No [11] 
di-Rh(II), tetra-
carboxylate 
complex 
Thermotoga	
maritima	tHisF 
covalent 
Cyclopropanation of styrene 
derivatives and carbene insertion 
into Si-H 
No [48] 
Pyrococcus 
furiosus prolyl 
oligopeptidase 
Cyclopropanation of styrene 
derivatives No [49] 
Rh(III), Cp*-
biotin 
Streptavidin 
Non-
covalent / 
supra-
molecular 
Asymmetric C-H activation No [50] 
Ir(III), Cp*-
biotin 
Artificial transfer hydrogenation 
(incl. cascades) No [19] 
Ru(II), 
Hoveyda-
Grubbs-biotin  
Olefin metathesis Yes [18] 
a in cases with multiple metals or screened proteins the most active or evolved ones are given 216 
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Scaffold Protein and Expression Strategy 217 
In principle, ArMs can be created from any scaffold protein into which the desired 218 
metal(-complex) can be anchored. Accordingly, several proteins from various host 219 
organisms have been used [5, 27]. In addition to practical requirements such as the 220 
ability to synthesize the protein in sufficiently high amounts (e.g. in E. coli), further 221 
considerations for scaffold selection apply for ArMs [6]. 222 
Stability under the required reaction conditions and evolvability are important 223 
requirements [6]. Therefore, proteins from thermophilic organisms are frequently 224 
selected as starting points for directed evolution campaigns because of their highly 225 
stable folds and tolerance to mutation [51, 52]. ArMs have recently been created from 226 
thermostable variants of a synthase from histidine biosynthesis [48, 53], a prolyl 227 
oligopeptidase [49], P450 cytochromes [11, 12, 46], and a cupin-like protein [54]. Other 228 
specifications can restrict the protein repertory further. Repurposing approaches, for 229 
instance, rely on intrinsic side reactivities, which sometimes requires screening to 230 
identify a suitable origin for directed evolution [12, 13]. Likewise, metal cofactor 231 
anchoring (vide infra) can limit the available range of candidate proteins significantly if 232 
inherent metal binding or affinity to supramolecular anchoring moieties is required. 233 
Once selected, the protein can be expressed in a desired host organism, which in the 234 
field of ArMs has thus far largely been performed in E. coli due to ease of cultivation 235 
and availability of versatile methods for genetic engineering. “Traditional” cytosolic 236 
expression is commonly used before purification using standard procedures (e.g. 237 
affinity chromatography). While useful to isolate preparative protein quantities, this 238 
strategy is not necessarily the best choice for whole cell and in vivo applications. In 239 
particular restricted cofactor uptake and inhibition of transition metal catalysis by 240 
cytosolic compounds may speak in favor of alternative production pathways like 241 
periplasmic or extracellular expression (vide infra). The former was successfully used 242 
by Song and Tezcan to create an artificial metallo-β-lactamase [17] and later by us to 243 
implement and evolve ArMs for olefin metathesis in E. coli [18].  244 
Although thus far largely under-appreciated in this specific context, other organisms 245 
may prove valuable, for instance for preparative ArM applications. The methylotrophic 246 
yeast Pichia pastoris, for example, is a potent, well-characterized host for high-yield 247 
secretory protein production, offers high solvent tolerance and access to cheap carbon 248 
and energy sources [55], and has been recently used for the production of a 249 
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streptavidin-based artificial imine reductase [56]. Similarly, other hosts including 250 
mammalian cells could facilitate future ArM development in vivo. 251 
 252 
Cofactor Uptake 253 
Another important aspect is cellular uptake of cofactors as a limitation for ArM usage 254 
in vivo in contrast to in vitro scenarios where the scaffold protein is freely accessible. 255 
In particular artificial cofactors with complex ligands frequently exceed the molecular 256 
weight exclusion cut-off of outer membrane porins (~600 Da) [57] and do not have 257 
access to a specific cellular uptake machinery like natural cofactors such as heme [58]. 258 
During our aforementioned study on artificial metathases, we identified the uptake of 259 
the ruthenium cofactor as a major bottleneck [18]. Although in vivo assembly and 260 
directed evolution was still feasible in spite of prevailing cofactor uptake limitations by 261 
adding surplus cofactor to the cells and subsequently eliminating excess by washing, 262 
a restricted cofactor uptake imposes major limitations for preparative whole cell and in 263 
vivo applications, since it reduces overall yield of the ArM reaction. Similar arguments 264 
may be made for non-permeable reaction substrates. 265 
In principle, uptake limitations can be overcome by different measures on both the 266 
chemical and biological side. They should be considered during initial cofactor design, 267 
and size reduction as well as chemical modification [59] are measures with potential to 268 
improve uptake. On the biological side, the scaffold protein can be expressed in the 269 
periplasm or on the cell surface to avoid requirement for cofactor transit through 270 
membranes (vide supra) [60]. Overexpression of suitable outer membrane transport 271 
proteins was shown to improve uptake of metal-substituted porphyrin derivatives [31, 272 
47, 61] and engineering of pore proteins may help to elevate the cut-off of the outer 273 
membrane [62]. Alternatively, the permeability of the cell envelope can be increased 274 
by chemical treatment. For E. coli we have observed improvement of cofactor uptake 275 
in presence of high salt concentrations, which are known to facilitate uptake of large 276 
compounds [63]. Wallace and Balskus suggested micelles to enhance 277 
cyclopropanation of styrene produced in situ by E. coli and suggest increased 278 
membrane permeability as contributing factor for the observed improvement [64]. 279 
 280 
Cofactor anchoring 281 
Quantitative and precise localization of metal cofactors within protein scaffolds is an 282 
important prerequisite to create functional and evolvable metalloenzymes. To this end, 283 
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several strategies have been pursued, which have been thoroughly reviewed 284 
previously (e.g. [3, 5, 6, 27]). While all of these strategies have successfully been 285 
applied in ArM assembly, they arguably differ significantly in view of their utility for 286 
whole cell and in vivo applications [60]. In this context, two main coupling modes, 287 
reactive covalent and spontaneous noncovalent coupling, can be distinguished. 288 
 289 
Reactive Coupling 290 
Covalent cofactor attachment to amino acid residues ensures stable anchoring and 291 
allows for a high degree of flexibility with respect to scaffold protein choice and metal 292 
positioning [5]. However, natural conjugative residues (lysine, cysteine) lack specificity 293 
in scenarios with multitudes of non-target proteins present in the reaction mixture 294 
where off-target binding is likely. To achieve bioorthogonality site-specific introduction 295 
of non-canonical residues by amber stop codon suppression can be used [65]. The 296 
group of Lewis introduced p-azido-L-phenylalanine within the pore of the  , -barrel 297 
protein tHisF [48] and later within a prolyl oligopeptidase [49] to conjugate different 298 
artificial cofactors by copper-free click chemistry. An alternative way to achieve higher 299 
specificity is the exploitation of active site residues for bioconjugation [5]. Eppinger 300 
demonstrated the coupling of rhodium and ruthenium half-sandwich complexes to the 301 
nucleophilic active site cysteine of papain relying on inhibitors for this protein to ensure 302 
both efficient bond formation via a reactive epoxide moiety and precise positioning by 303 
non-covalent interaction [66]. This allowed for ArM assembly at substoichiometric 304 
cofactor-to-protein ratios and the creation of an enantioselective hydrogenation 305 
biocatalyst from achiral metal complexes. 306 
However, covalent ArM assembly in complex biological systems remains challenging. 307 
Major obstacles include limitations in biocompatibility (toxicity) and bioorthogonality 308 
(cross-reactivity), inefficiency of non-canonical residue introduction, and poor 309 
efficiency of the coupling reaction. The latter imposes the use of multiple cofactor 310 
equivalents to achieve quantitative protein conjugation [60]. 311 
 312 
Spontaneous Non-Covalent Coupling 313 
A conceptually different approach builds on anchoring of the metal(-complex) via 314 
noncovalent interactions. In analogy to many natural metalloenzymes, efforts for ArM 315 
creation have been reported that rely on the assembly of active sites by direct 316 
interaction of the metal with coordinating residues such as histidine [5, 27]. In this case 317 
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the metal’s first ligand sphere is partially or fully completed by the protein and assembly 318 
occurs spontaneously, rendering complicated and potentially detrimental reactive 319 
steps dispensable. To this end, ArMs can be created by re-purposing of natural metal-320 
binding sites, either building on catalytic promiscuity of the native metal or by 321 
reconstitution with nonnative metals. Particularly noteworthy studies include the 322 
computational redesign and directed evolution of a zinc deaminase to an 323 
organophosphate hydrolase [43] and the reconstitution of a manganese-binding 324 
protein from the cupin family with osmium(VI) resulting in a thermostable artificial 325 
peroxygenase with high TON [54]. Alternatively, metal centers can be created de novo 326 
based on existing or fully synthetic protein folds [17, 40, 42, 67]. Based on earlier works 327 
of Lee and Schultz [68], the group of Roelfes used amber suppression to introduce the 328 
non-canonical amino acid (2,2’-bipyridine-5yl)alanine into the transcription factor LmrR 329 
in vivo thereby creating an ArM for asymmetric Friedel-Crafts alkylation [69]. This 330 
bidentate ligand allows for straightforward site-specific introduction of metal-chelating 331 
capacity simplifying active site creation by dative interaction. 332 
The natural prosthetic group heme as well as synthetic derivatives thereof have been 333 
extensively studied in the context of enzyme re-purposing and ArM creation (for 334 
comprehensive reviews please refer to [3, 7, 27]). Arguably, natural heme proteins and 335 
enzymes exhibit high affinity and specificity for the porphyrin scaffold, which renders 336 
holoenzyme assembly comparably simple. This has been exploited for ArM creation 337 
relying either on catalytic promiscuity of natural iron cofactor [12-16, 28, 29, 31, 33, 38] 338 
or by introducing synthetic derivatives of the latter [11, 31, 44-47]. Moreover, the 339 
available natural transport machinery for heme may be exploited to enhance cofactor 340 
uptake (vide supra) [47]. Importantly, reconstitution of proteins with non-native metals 341 
requires either ability to directly express the apoprotein or to retrieve it by removal of 342 
bound metal ex post (e.g. by dialysis) [5]. This premise, which stems from the lower 343 
affinity of non-native versus native metal, imposes additional challenges on the in vivo 344 
assembly of these ArMs. To overcome this limitation, Brustad and colleagues evolved 345 
a cytochrome P450 variant that selectively binds non-proteinogenic iron 346 
deuteroporphyrin IX in vivo over endogenous heme, thereby creating an orthogonal 347 
enzyme-cofactor pair [47]. 348 
Lastly, introduction of catalytic metals into proteins has been achieved via high-affinity 349 
protein-ligand interaction frequently referred to as supramolecular or “Trojan horse” 350 
strategy [5]. Although this approach limits the scope of target proteins to those that 351 
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exhibit sufficiently strong interaction with suitable anchoring moieties, it has several 352 
compelling assets for in vivo applications [60]: First, assembly occurs spontaneously 353 
upon mixing of scaffold protein and cofactor in solution without reactive coupling or 354 
prior binding site design and optimization. Second, metal anchoring is specific and 355 
essentially quantitative even at equimolar protein-cofactor ratios (provided sufficient 356 
affinity). And third, modular separation of catalytic and anchoring moiety allows for 357 
facile exchange of host proteins for given catalysts and similarly swapping of catalytic 358 
functionality in the same scaffold. Amongst supramolecular approaches the (strept-359 
)avidin-biotin technology is likely the most widespread and versatile one. This may be 360 
traced back to: i) the nearly irreversible biotin binding (KD ~ 10-14 M), which is exploited 361 
in several applications outside the domain of ArMs and ii) high chemical and physical 362 
stability of (strept-)avidin. These properties have led to a diverse array of ArMs with 363 
several catalytic metals and target reactions, which has been reviewed elsewhere (e.g. 364 
[3, 5]). Furthermore, other protein-ligand pairs have been used for ArM construction 365 
including carbonic anhydrase and cognate sulfonamide inhibitors [70, 71], xylanase 366 
with carboxylated porphyrin derivatives [72, 73], and β-lactoglobulin and aliphatic 367 
chains [74]. 368 
 369 
Inhibition and Toxicity 370 
In contrast to defined in vitro scenarios, ArM application in vivo requires consideration 371 
of mutual interactions between the (ideally bio-orthogonal) ArM and the host. This 372 
comprises inhibition of catalysis by cellular components as well as toxicity of the ArM 373 
(reaction) against the host cell. Glutathione has been identified as a major inhibitor of 374 
transition metal reactions in cell lysates [18, 75], likely due to formation of metal-thiolate 375 
complexes, and other cell-derived agents such as proteins, nucleic acids and reactive 376 
or chelating metabolites come to mind as potential poisons. While shielding of the 377 
cofactor by the protein can enhance stability [18, 49]), additional measures are 378 
required to avoid the said limitations. Quenchers can diminish inhibition, which has 379 
been capitalized on using diamide to oxidize thiols in cell lysates in ArM-catalyzed 380 
asymmetric transfer hydrogenation [75] or by application of reducing agents (e.g. 381 
sodium dithionite) and anaerobic conditions for oxygen-sensitive reactions [12, 13, 16, 382 
28, 38]. However, biocompatibility of the quencher has to be taken into account for in 383 
vivo applications. Alternatively, placing the ArM in another compartment, the 384 
periplasm, whose oxidative environment lacks large amounts of free thiols and other 385 
p. 14 / 19 
 
potentially detrimental agents from the cytosol, has been succesfully used for ArM 386 
development [17, 18, 60]. 387 
Besides catalyst poisoning, cytotoxicity is a major barrier hindering in vivo applicability 388 
of many ArM reactions. It can be caused by the ArM as such, by substrates, 389 
intermediates and products of the corresponding reaction, or by additives. Notably, 390 
some recent works in the ArM field involve biotransformations with whole cells of 391 
E. coli, which has the potential to simplify production and represents a first step 392 
towards in vivo utilization. However, most of these studies apply conditions limiting 393 
their in vivo utility including the presence of significant amounts of cytotoxic agents 394 
such as organic solvents, styrene (derivatives), diazo compounds, and azides as well 395 
as strict anaerobic conditions enforced by oxygen stripping and reductants. 396 
Use of biocompatible solvents such as dimethyl sulfoxide, stepwise substrate addition, 397 
and in situ product removal can help to mitigate toxic effects. To this end, vitamin E-398 
derived micelles were shown to elevate styrene production in E. coli beyond toxicity 399 
limits, which was exploited for iron-catalyzed in situ cyclopropanation (no ArM) under 400 
aerobic conditions [64, 76]. The group of Fasan recently reported on a two-vessel setup 401 
for ex situ generation of highly toxic and volatile 2-diazo-1,1,1-trifluoroethane, which 402 
was used as carbene donor in myoglobin-catalyzed cyclopropanation of styrene 403 
derivatives using E. coli cells [15]. 404 
Importantly, due to a plethora of potential contributors to the global phenomenon of 405 
cytotoxicity, it is arguably difficult to address in a generic manner, and careful 406 
evaluation is necessary for individual ArMs. 407 
 408 
Concluding Remarks and Future Perspectives 409 
 410 
As highlighted in this synopsis, ArMs constitute a promising technology merging crucial 411 
assets of transition metal catalysis and enzymology, which can be exploited to create 412 
new biocatalysts for organic synthesis and to expand Nature’s enzymatic arsenal. 413 
From the chemist’s viewpoint, this concept can be readily applied for transformations 414 
of ever increasing intricacy and with efficiencies approaching economic viability. On 415 
the contrary, the synthetic biology angle has hitherto been largely underappreciated, 416 
very likely due to limitations of ArM applicability in living cells. 417 
Full integration of ArMs into metabolic networks of cells, however, holds great promises 418 
for future applications. Firstly, it will allow to apply the entire potential of laboratory 419 
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evolution to these new biocatalysts, which will dramatically increase pace and 420 
throughput of optimization and enable the development of ArMs with highly improved 421 
and entirely novel catalytic properties. To this end, ArMs could be subjected to high-422 
throughput screening assays without the need for extensive processing procedures 423 
[18]. Moreover, Darwinian selection schemes, in which ArM reactions are causally 424 
coupled to the survival or proliferation of the host organism, could be applied, which 425 
enables retrieval of improved variants from extremely large pools via competitive one-426 
pot growth experiments. Second, in vivo integration of new reactivities by ArMs (and 427 
other artificial enzymes) will eventually allow for implementation of novel metabolic 428 
routes for sustainable production of previously inaccessible chemicals from renewable 429 
feedstocks [77-79]. Lastly, beyond the aforementioned synthetic applications, 430 
transition metal catalysis and consequently ArMs could be used for biochemical and 431 
medical applications, which was not outlined herein but elaborated on elsewhere (e.g. 432 
[24, 25, 80]). 433 
In quintessence, the assimilation of ArMs by living cells is a highly auspicious, yet 434 
challenging, endeavor and may contribute to a future “fourth wave” of biocatalysis 435 
following Bornscheuer’s metaphor [1]. 436 
 437 
<Outstanding Questions Box> 438 
What are the most pressing chemical challenges that ArMs could solve? 439 
Will ArMs be able to make it “out of the niche” by outcompeting small molecule 440 
catalysts in large scales and for wide applications in the near future and can they 441 
contribute to the transition towards a sustainable, bio-based economy? 442 
Can we combine multiple ArMs and natural enzymes with each other to engineer entire 443 
artificial pathways in living organisms, which lead to the production of previously 444 
inaccessible bio-products and what will the latter look like? 445 
Is it possible to systematically install functional ArMs in living organisms that are 446 
propagating in the presence of the ArM reaction or even benefit from it and what is the 447 
potential of bringing non-natural metals (e.g. iridium, ruthenium, rhodium, palladium, 448 
gold, osmium etc.) into synthetic biology? 449 
Will we be able to establish biosynthesis of non-canonical cofactors to render their 450 
addition to the cells obsolete? 451 
What is the potential of in vivo utilization of ArMs beyond bio-production and 452 
preparative chemistry? <\Outstanding Questions Box> 453 
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